menu
    • menu
    [{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ University College London","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ University College London"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Merck"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Hande Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Hande Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Hande Sciences"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for QN-302

    Menu

    QN-302

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatmen...

                            Details : QN-302 is a small molecule G-Quadruplex (G4)-selective transcription inhibitor in Phase 1 clinical development for the treatment of G4-expressing solid tumors, such as pancreatic cancer (PDAC), prostate cancer, sarcomas, and others.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 01, 2023

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

                            Details : QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, ...

                            Details : QN-302 (formerly SOP1812) is a G4 selective transcription inhibitor. QN-302 is a small molecule drug candidate with superior efficacy and activity against pancreatic cancer.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 10, 2023

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for t...

                            Details : The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2022

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting

                            Details : QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 14, 2022

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Hande Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabl...

                            Details : QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for Pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need, such as Prostate Cancer.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 06, 2022

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Hande Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

                            Details : QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for PDAC, in addition to other tumors of high unmet clinical need.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 07, 2022

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference

                            Details : QN-302, genomic quadruplex (G4)-selective transcription inhibitor demonstrated potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic prostate cancer.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 12, 2022

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

                            Details : QN-302 is Qualigen’s genomic quadruplex (G4)-selective transcription inhibitor platform with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing G4s against “unwinding,” help inhibit cancer cell proliferatio...

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2022

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Qualigen Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conferenc...

                            Details : QN-302 is the Company’s genomic quadruplex (G4)-selective transcription inhibitor being developed as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need.

                            Brand Name : QN-302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2022

                            Lead Product(s) : QN-302

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth